Recent Analysts’ Ratings Updates for Celcuity (CELC)

A number of research firms have changed their ratings and price targets for Celcuity (NASDAQ: CELC):

• 6/4/2026 – Celcuity was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/3/2026 – Celcuity had its price target lowered by Craig Hallum from $189.00 to $171.00. They now have a “buy” rating on the stock.
• 6/3/2026 – Celcuity had its “buy” rating reaffirmed by Guggenheim.
• 6/3/2026 – Celcuity had its price target lowered by Wells Fargo & Company from $183.00 to $166.00. They now have an “overweight” rating on the stock.
• 6/3/2026 – Celcuity had its price target lowered by HC Wainwright from $185.00 to $145.00. They now have a “buy” rating on the stock.
• 6/2/2026 – Celcuity was given a new $155.00 price target by Leerink Partners.
• 5/28/2026 – Celcuity was given a new $160.00 price target by Macquarie Infrastructure Holdings, LLC.
• 5/28/2026 – Celcuity had its “market outperform” rating reaffirmed by Citigroup Inc..
• 5/19/2026 – Celcuity was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/18/2026 – Celcuity had its price target raised by HC Wainwright from $165.00 to $185.00. They now have a “buy” rating on the stock.
• 5/15/2026 – Celcuity had its price target raised by Wells Fargo & Company from $150.00 to $183.00. They now have an “overweight” rating on the stock.
• 5/15/2026 – Celcuity had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $157.00 price target on the stock.
• 5/4/2026 – Celcuity had its “buy” rating reaffirmed by Craig Hallum. They now have a $189.00 price target on the stock.
• 5/4/2026 – Celcuity had its price target raised by Guggenheim from $135.00 to $165.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Celcuity was given a new $150.00 price target by Stifel Nicolaus.
• 5/4/2026 – Celcuity had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/4/2026 – Celcuity had its price target raised by Citizens Jmp from $150.00 to $160.00. They now have a “market outperform” rating on the stock.
• 5/4/2026 – Celcuity had its price target raised by Needham & Company LLC from $122.00 to $157.00. They now have a “buy” rating on the stock.
• 4/27/2026 – Celcuity is now covered by Citigroup Inc.. They set an “outperform” rating on the stock.
• 4/27/2026 – Celcuity is now covered by Citizens Jmp. They set a “market outperform” rating and a $150.00 price target on the stock.
• 4/25/2026 – Celcuity was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/20/2026 – Celcuity had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the sale, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This represents a 27.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 37,000 shares of company stock valued at $5,111,950. 13.33% of the stock is owned by corporate insiders.

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.